Professor Nir Peled Joins SciSparc's Advisory Board
Professor Nir Peled, a distinguished oncologist, has been appointed to the Scientific Advisory Board of MitoCareX Bio Ltd. This collaborative effort is between SciSparc Ltd. (NASDAQ: SPRC) and Dr. Alon Silberman. This new role highlights SciSparc's dedication to pioneering cancer treatments and its goal of developing therapies for disorders affecting the central nervous system.
About Professor Nir Peled
Currently, Professor Nir Peled is the Director of the Oncology Department at Shaare Zedek Medical Center in Jerusalem. He is board certified in internal medicine, pulmonology, and medical oncology, and is widely recognized as a leading authority in thoracic oncology. His contributions to lung cancer research and treatment have gained him international recognition.
Accomplishments in Oncology
Professor Peled has held several prestigious positions, including serving on the board of the International Association for the Study of Lung Cancer (IASLC) and chairing the Global Multidisciplinary Practice Standards Committee. He recently concluded his term as Chair of the Thoracic Cancer Assembly of the European Thoracic Society. His research primarily revolves around personalized targeted therapy, immunotherapy, cancer evolution, and biomarker development, which have greatly advanced early detection of lung cancer. He has authored over 250 peer-reviewed papers in these fields.
Innovation and Research at MitoCareX
Dr. Alon Silberman, CEO of MitoCareX, expressed enthusiasm about Professor Peled joining the team, highlighting the significance of his expertise in enhancing the company's cancer treatment technologies. MitoCareX is dedicated to drug discovery and development for life-threatening conditions, particularly focusing on research related to the mitochondrial SLC25 protein family.
Advances in Lung Cancer Research
A key achievement for MitoCareX has been the validation of the SLC25 carrier protein's role in Non-Small Cell Lung Cancer (NSCLC). This breakthrough was made possible through advanced genetic manipulation techniques and 3D spheroid systems that simulate human tumors.
The company employs a sophisticated computational platform, including its proprietary MITOLINE™ algorithm, to screen millions of small molecules, resulting in the discovery of numerous potential anti-cancer treatments. This work has significantly broadened MitoCareX's therapeutic pipeline.
About SciSparc Ltd.
SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in the development of cannabinoid-based therapies. Its primary programs include SCI-110 for Tourette Syndrome and agitation in Alzheimer’s disease, SCI-160 for pain management, and SCI-210 for treating autism spectrum disorder and status epilepticus. The experienced team at SciSparc is dedicated to advancing cannabinoid pharmaceutical technologies.
Strategic Growth and Future Plans
SciSparc is consistently enhancing its drug development portfolio while investigating the therapeutic potential of cannabinoid medications. The company also maintains a controlling interest in a subsidiary that focuses on hemp seed oil products sold on Amazon Marketplace, positioning itself for strategic growth across various health markets.
Frequently Asked Questions
Who is Professor Nir Peled?
Professor Nir Peled is a prominent oncologist who has joined the Scientific Advisory Board of MitoCareX, bringing his expertise in thoracic oncology.
What is MitoCareX?
MitoCareX is a collaboration with SciSparc that focuses on drug discovery and development aimed at targeting mitochondrial SLC25 proteins for cancer therapies.
What role will Professor Peled play at MitoCareX?
He will offer valuable insights and guidance to help advance the company's innovative cancer treatment technologies.
What are SciSparc's main drug development focus areas?
SciSparc is primarily focused on cannabinoid-based treatments for conditions such as Tourette Syndrome, Alzheimer's disease, pain management, and autism spectrum disorder.
How is MitoCareX advancing cancer therapy?
MitoCareX employs advanced computational drug discovery methods and validation studies to identify promising small molecules for cancer treatment.
